Capital Fund Management S.A. Acquires 64,078 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Capital Fund Management S.A. increased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 180.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 99,573 shares of the medical equipment provider's stock after purchasing an additional 64,078 shares during the quarter. Capital Fund Management S.A. owned approximately 0.14% of Lantheus worth $8,908,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Geode Capital Management LLC raised its holdings in Lantheus by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider's stock valued at $184,798,000 after buying an additional 32,551 shares during the last quarter. Reinhart Partners LLC. raised its stake in shares of Lantheus by 9.9% during the fourth quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider's stock valued at $122,280,000 after acquiring an additional 123,282 shares during the last quarter. Swedbank AB lifted its holdings in shares of Lantheus by 53.3% during the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock worth $99,054,000 after purchasing an additional 385,000 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Lantheus in the fourth quarter worth $36,183,000. Finally, Boston Partners increased its holdings in Lantheus by 57.5% in the fourth quarter. Boston Partners now owns 400,797 shares of the medical equipment provider's stock valued at $36,201,000 after purchasing an additional 146,268 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Lantheus

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares of the company's stock, valued at $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 63,109 shares of company stock worth $6,016,046. Insiders own 1.50% of the company's stock.

Lantheus Price Performance

Shares of LNTH traded up $0.03 during trading hours on Thursday, hitting $100.55. The stock had a trading volume of 176,142 shares, compared to its average volume of 952,624. The firm has a 50 day simple moving average of $94.71 and a 200-day simple moving average of $95.61. The firm has a market capitalization of $6.89 billion, a P/E ratio of 16.71 and a beta of 0.20. Lantheus Holdings, Inc. has a 1-year low of $61.46 and a 1-year high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Equities analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on LNTH shares. Truist Financial upped their price target on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. The Goldman Sachs Group initiated coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a "buy" rating and a $143.00 target price for the company. B. Riley dropped their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. Finally, JMP Securities reiterated a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, Lantheus currently has a consensus rating of "Moderate Buy" and a consensus price target of $129.43.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.